HR 5547
Maintaining Investments in New Innovation Act
Take action
Record your position on this measure.
Sign in to record your position, submit testimony, or contact your legislator.
Sign in to take action- Introduced
- Passed House
- Passed Senate
- To President
- Became Law
Bill overview
This bill, the Maintaining Investments in New Innovation Act, changes the requirements for prescription drugs to be included in Medicare’s drug price negotiation program. Specifically, it raises the minimum market approval time required for drugs to qualify from 7 years to 11 years. This change applies to drugs that utilize ‘genetically targeted technology,’ a category defined by the Food and Drug Administration. The goal is to protect access to newer, innovative medications while allowing the government to negotiate their prices.
Sponsors
Official sponsors from legislative records.
Primary sponsor
Wiley Nickel
Cosponsors
A. Drew, IV Ferguson
Arguments in favor
Reasons to support this legislation.
No arguments in favor have been submitted.
Submit yoursArguments opposed
Reasons to oppose this legislation.
No arguments opposed have been submitted.
Submit yoursRead the latest version inline or switch to a previous version.